1. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study. Issue 5 (28th May 2021) Authors: Vijiaratnam, Nirosen; Girges, Christine; Auld, Grace; Chau, Marisa; Maclagan, Kate; King, Alexa; Skene, Simon; Chowdhury, Kashfia; Hibbert, Steve; Morris, Huw; Limousin, Patricia; Athauda, Dilan; Carroll, Camille B; Hu, Michele T; Silverdale, Monty; Duncan, Gordon W; Chaudhuri, Ray; Lo, Christine... Journal: BMJ open Issue: Volume 11:Issue 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Issue 10103 (7th October 2017) Authors: Athauda, Dilan; Maclagan, Kate; Skene, Simon S; Bajwa-Joseph, Martha; Letchford, Dawn; Chowdhury, Kashfia; Hibbert, Steve; Budnik, Natalia; Zampedri, Luca; Dickson, John; Li, Yazhou; Aviles-Olmos, Iciar; Warner, Thomas T; Limousin, Patricia; Lees, Andrew J; Greig, Nigel H; Tebbs, Susan; Foltynie,... Journal: Lancet Issue: Volume 390:Issue 10103(2017) Page Start: 1664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Post hoc analysis of the Exenatide‐PD trial—Factors that predict response. (6th October 2018) Authors: Athauda, Dilan; Maclagan, Kate; Budnik, Natalia; Zampedri, Luca; Hibbert, Steve; Aviles‐Olmos, Iciar; Chowdhury, Kashfia; Skene, Simon S.; Limousin, Patricia; Foltynie, Thomas Journal: European journal of neuroscience Issue: Volume 49:Number 3(2019) Page Start: 410 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗